Blood Dialyzer Market Valued to be US$ 7,905.6 Million with CAGR of 6.1% from 2022 to 2027 | Nipro Corporation, CVS Health., Diaverum Deutschland GmbH, NxStage Medical

Global Blood Dialyzer Market

Dialysis is a treatment given to patients in the later stages of renal failure (chronic renal insufficiency). These treatments are achieved using an assembly called a dialyzer, which cleans the blood and removes waste and excess fluid from the body that is normally removed by healthy kidneys. In haemodialysis, blood is removed from the body and circulated through the extracorporeal fluid circuit (outside the body), then returns to the body. The hemodialyzer selectively encloses a permeable membrane that acts as a filter that allows fluid and waste to pass through.

The increasing incidence of acute kidney disease is expected to increase the number of dialysis procedures, leading to an increase in the blood dialysis market in the estimated period. For example, according to the Global Kidney Health Atlas April 2017, one in three of the general population is at risk of acute kidney disease, and approximately 10% of people worldwide had acute kidney disease (CKD) in 2017. Furthermore, estimates indicate that 9 out of 10 CKD sufferers are unaware of their condition.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞 𝐰𝐢𝐭𝐡 𝐋𝐚𝐭𝐞𝐬𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 @ https://www.coherentmarketinsights.com/insight/request-pdf/2503

Global Blood Dialyzer Market: Drivers

Manufacturers are engaged in intensifying its services by expanding production units and joint ventures. For example, in December 2017, Japan’s Nikkiso Co. Ltd partnered with China-based Shandong Weigao Group Medical Polymer Company to increase the production of dialysis in China by five times by 2020 and up to 20,000 units per year.

In addition, key players are focusing on launching new products to maximize access to its products to end users and instead increase its market share. For example, in September 2016, B. Braun Medical Inc., after 501 (k) approval by the FDA, launched the Xevonta Kidney Dialyzer. This dialyzer will be available in the US market. Zeventa Kidney Dialyzer’s innovative membrane technology aims to improve clearance performance by removing excess toxins from patients’ blood.

Also, in May 2017, NxStage Medical, Inc. received approval from the FDA for the next generation haemodialysis system. It includes new features and capabilities, including a touchscreen user interface and an integrated blood pressure monitor, designed to make it easier for patients to use for home haemodialysis.

𝐓𝐨 𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐰𝐢𝐭𝐡 𝐋𝐚𝐭𝐞𝐬𝐭 𝐂𝐨𝐯𝐢𝐝𝟏𝟗 𝐈𝐦𝐩𝐚𝐜𝐭 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬 @ https://www.coherentmarketinsights.com/insight/request-sample/2503

Furthermore, increasing government initiatives to promote improved treatment options for patients with renal failure have helped producers grow significantly in the global blood dialyser market. For example, in September 2018, the US Department of Health and Human Services (HHS) and the American Society of Nephrology (ASN) set aside a prize money of US $ 2,265,000 for KidneyX: redesign dialysis. This competition challenges manufacturers to develop better treatment options for patients with renal failure. Thus, HHS is anticipating innovations in the area of ​​dialysis and dialyzer membranes that will restructure the treatment of renal failure.

The size of the global blood dialyzer market size was valued at US$ 4,682.7 million in 2017, and during the estimated period (2018-2026). It is likely to witness a CAGR of 6.1%.

Global Blood Dialyzer Market: Key Takeaways

• Depending on the type of product, the maximum increase in disposable dialysers is expected, as are the risks associated with reusable dialysers.
• Depending on the dialysis membrane content, the synthetic cellulose segment is expected to receive maximum traction with the launch of the new product. For example, in November 2017, Nipro Medical Corporation announced the launch of Cellentia-H Cellulose Triacetate (CTA), a single-use dialyzer, at the 2017 ASN Kidney Week Conference. The cellulose trisetate membrane optimizes excellent biocompatibility and clearance to minimize potential adverse reactions. Cellentia-H is also gamma sterilized to enhance product safety and disinfection. The advancement of such technology in blood dialysers has encouraged its growth in the global market in the forecast period.

Global Blood Dialyzer Market- Competitive Landscape

Key players performing in the global blood dialyzer market are DaVita Healthcare Partners, Inc., Fresenius Medical Care AG & Co. KGaA, NxStage Medical, Inc., Diaverum Deutschland GmbH, CVS Health., Nipro Corporation, B. Braun Medical Inc., Nikkiso Co. Ltd., and Baxter International, Inc.